Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"Meeting Report From the 2024 Symposium on IRAK4 in Cancer: Highlights and Clinical Updates.","authors":"Eric S Winer, Marina Konopleva, Han W Tun, Kian-Huat Lim, Bently Doonan, Klaus H Metzeler, Lakshmi Nayak, Andrés J M Ferreri, Christina von Roemeling, Grzegorz S Nowakowski, Guillermo Garcia-Manero","doi":"10.1016/j.clml.2025.05.020","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.020","url":null,"abstract":"<p><p>Interleukin-1 receptor-associated kinase 4 (IRAK4) is a serine/threonine kinase that mediates interleukin-1 and Toll-like receptor (TLR) signaling. IRAK4 drives the activation of nuclear factor kappa B (NF-κB), which promotes cell survival, inflammation, and proliferation. Aberrant activation of IRAK4 and TLR signaling has been implicated in multiple malignancies. At the 3rd Annual IRAK4 in Cancer Symposium, experts discussed the role of IRAK4 in cancer biology, the potential for synergism between IRAK4 inhibition and other treatments to overcome resistance, and how IRAK4 inhibition may improve clinical outcomes. Preclinical data were presented demonstrating the activity of IRAK4 inhibition alone or in combination with other anticancer agents in acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma, primary central nervous system lymphoma, melanoma brain metastases, gastrointestinal cancers, and pancreatic ductal adenocarcinoma. Clinical data from the targeted small-molecule IRAK4 inhibitor emavusertib (CA-4948) were presented, including data from the TakeAim Leukemia and TakeAim Lymphoma trials of emavusertib in myeloid and lymphoid malignancies, respectively, and preliminary data from trials of emavusertib in multiple solid tumors. The meeting closed with expert discussion of the emerging profile of IRAK4 inhibition in cancers and the potential for IRAK4 inhibition to improve outcomes across both solid and liquid tumors.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | Does Limited Stage Diffuse Large B-cell Lymphoma Matter?","authors":"Arina Martynchyk, Eliza A Hawkes","doi":"10.1016/j.clml.2025.05.018","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.018","url":null,"abstract":"<p><p>Limited stage diffuse large B-cell lymphoma (LSDLBCL) has excellent outcomes, but progress in management has been plagued by lack of standard definitions and exclusion from many trials evaluating novel agents in advanced stage DLBCL (ASDLBCL) which increasingly target high-risk populations. LSDLBCL definition varies but is most commonly defined as Ann Arbor stage I-II nonbulky disease (< 10 cm). LSDLBCL patient long-term survival exceeds 90% when treated with standard courses (6-8 cycles) of chemoimmunotherapy (CIT). Attempts have therefore been made to minimize CIT toxicity via fewer cycles, employing radiotherapy or positron emission tomography (PET)-adapted CIT instead. This has led to significant variation and complexity in LSDLBCL treatment, not least because LSDLBCL definition and trial eligibility have lacked consistency. Four key dedicated LSDLBCL treatment paradigms have evolved beyond the standard 6-8 RCHOP cycles given to ASDLBCL, such as Combined Modality Treatment (CMT), PET-adapted CMT and PET-directed RT, abbreviated RCHOP for young patients with no poor risk factors and PET-adapted CIT. Greater understanding of the biology and risk profiles of LSDLBCL matters, as does tailoring treatment in this unique disease. Ongoing international collaborative efforts to refine treatment paradigms according to risk are required to improve outcomes in these patients. Novel therapy studies should also be part of the immediate research agenda.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Perspectives on Amyloidosis in India: A Systematic Literature Review.","authors":"Sumeet Mirgh, Uday Yanamandra, Ganesh K Vishvanathan, Sadashivudu Gundeti, Navin Khattry, M Joseph John, Pankaj Malhotra, Hari Menon, Satyaranjan Das, Reena Nair, Velu Nair, Tapan Saikia, Shaji K Kumar","doi":"10.1016/j.clml.2025.05.014","DOIUrl":"10.1016/j.clml.2025.05.014","url":null,"abstract":"<p><strong>Background: </strong>Amyloidosis is a condition characterized by deposition of insoluble protein fibrils in tissues, leading to diverse clinical manifestations. There is limited data addressing amyloidosis from India.</p><p><strong>Objective: </strong>This study aims to systematically review the available clinical data on amyloidosis in India. By synthesizing existing knowledge, the review seeks to identify research gaps that require further exploration.</p><p><strong>Methods: </strong>A systematic review was conducted using the PubMed database to identify English-language articles on amyloidosis from India published between 1959-2023. Additionally, abstracts from international conferences were analyzed. Data extracted were-type of amyloidosis, demographics, clinical presentation, diagnostic methods, and outcomes.</p><p><strong>Results: </strong>The median age at presentation in Indian patients was approximately 10 years younger (50 years) compared to their counterparts in Western countries (60 years), with males comprising 70% of the cases. Renal involvement was the most common, with AA being more prevalent than AL amyloidosis, often secondary to tuberculosis. Cardiac involvement was second most common, affecting 40%-50% of patients. In patients with paraproteinemic neuropathies, AL amyloidosis accounts for the cause in 4% cases. Treatment of AL amyloidosis primarily involved chemotherapy and supportive care, with autologous transplantation underutilized due to resource limitations. Amongst localized amyloidosis, skin was the most common site (68% of all cases).</p><p><strong>Conclusion: </strong>Amyloidosis in India remains a significant and often underdiagnosed condition, with varied presentations and causes. Most data come from retrospective studies, highlighting variability in presentation and outcomes. This review underscores the importance of understanding the disease burden and advancing research to improve outcomes in India.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study.","authors":"Benoit Tessoulin, James Harnett, Seok-Goo Cho, Michał Taszner, Tae Min Kim, Silvana Novelli, Jose C Villasboas, Michele Merli, Ana Jiménez-Ubieto, Michelle Poon, David Tucker, Jan Walewski, Shuhua Yi, Yuqin Song, Geoffrey Chong, Emmanuel Bachy, Stephanie Guidez, Aranzazu Alonso, Deepa Jagadeesh, Wei Zhang, Laura Magnano Mayer, Elżbieta Iskierka-Jażdżewska, Monica Tani, Jingxian Cai, Cristina Ivanescu, Matthew Reaney, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Lei Chi, Siddhesh Kamat, Stefano Luminari","doi":"10.1016/j.clml.2025.05.017","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.017","url":null,"abstract":"<p><strong>Background: </strong>In ELM-2, the human CD20 × CD3 bispecific antibody odronextamab was associated with deep, durable responses and a generally manageable safety profile in patients with relapsed/refractory follicular lymphoma (r/r FL).</p><p><strong>Patients and methods: </strong>Prespecified analyses reported herein examined patient-reported outcomes in ELM-2 among 140 patients with r/r FL.</p><p><strong>Results: </strong>Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), patients reported good global health status/quality of life (GHS/QoL), functioning, and low symptom burden at baseline, which were generally maintained. Emotional functioning improved significantly overall, with a clinically meaningful change at week 42. Patients were more likely to report clinically meaningful improvement or maintenance than worsening on QLQ-C30 scales. Median time to definitive deterioration (TTDD) was 22.4 months for GHS/QoL, 22.6 months for role functioning, 19.8 months for social functioning, 16.4 months for cognitive functioning, and not reached for physical functioning or emotional functioning. For each QLQ-C30 symptom scale, median TTDD was > 15 months or not reached. On the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) questionnaire, Lymphoma Subscale (LymS) scores improved significantly overall, with clinically meaningful improvement at weeks 26 and 42, and FACT-G, Trial Outcome Index, and Total Score were maintained. Most patients reported either limited or no bother related to side effects of treatment. Visual analog scale scores of the EQ-5D-3L questionnaire improved significantly overall.</p><p><strong>Conclusion: </strong>In this heavily pretreated, highly refractory population, maintenance or improvement of health-related quality of life, functioning, and symptoms support odronextamab as a potential treatment option in R/R FL.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in India.","authors":"Smeeta Gajendra, Tanima Dwivedi, Karthik Bommannan, Ranjit Kumar Sahoo, Nupur Das, Prashant Tembhare, Khaliqur Rahman, Ajay Gogia, Raja Pramanik, Nitin Dayal, Rakhee Kar, Jyoti Kotwal, Sanjeev, Asish Rath, Diksha Dev, Ganesh Kumar Viswanathan, Man Updesh Singh Sachdeva, Mukul Aggarwal, Devasis Panda, Prashant Mehta, Sreejesh Sreedharanunni, Uday Yanamandra, Arun Kumar Arunachalam, Bhausaheb Bagal, Prabhat S Malik, Anil Handoo, Sanjeev Kumar Gupta, Sameer Bakhshi, Atul Sharma, Deepak Kumar Mishra, Pankaj Malhotra, Lalit Kumar, Ritu Gupta","doi":"10.1016/j.clml.2025.05.016","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.016","url":null,"abstract":"<p><strong>Background: </strong>Measurable residual disease (MRD) is becoming a cornerstone in the multiple myeloma (MM) management; however, its implementation in India faces several challenges. This Delphi survey aimed to gather expert consensus on the current practices, and barriers in MRD monitoring in MM in India.</p><p><strong>Methods: </strong>A 3-round Delphi process (2 e-surveys and 1 in-person meeting) was conducted with hematologists, pathologists, and oncologists managing MM in India. Consensus (≥ 75% agreement) led to recommendations for standardized MRD practices.</p><p><strong>Results: </strong>Twenty-five experts participated, agreeing on key protocols: processing first-pull bone marrow aspirates within 24 hours, using a single tube with at least a 10-color panel, acquiring at least 3 million events for 10⁻⁵ sensitivity under proper environmental control, and by adequately trained staff. At least 4 monoclonal antibodies for gating of plasma cells and at least 3 parameters among mast cells, myeloid precursors, hematogones, normal plasma cells, should be used to assess hemodilution. Guidance on modulation of treatment decisions, including maintenance therapy based on MRD status remains inconclusive. Though, there is an agreement that MRD negativity in MM improves survival and lowers relapse risk but currently it does not influence maintenance therapy decisions. MRD testing was advised at postinduction, pre/post-transplant, and annually during maintenance. Challenges identified included protocol variability, interpretation issues, and lack of an external quality assessment program. Experts emphasized the need for advanced flow cytometry training.</p><p><strong>Conclusions: </strong>The findings of this study will guide clinical adoption and future research, particularly for high-risk populations and novel therapies.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study.","authors":"Alexis Talbot, Cyrille Hulin, Aurore Perrot, Margaret Macro, Karim Belhadj Merzoug, Mohamed Mohty, Arthur Bobin, Lionel Karlin, Salomon Manier, Laure Vincent, Abderrazak El Yamani, Wajed Abarah, Regis Kaphan, Thomas Chalopin, Daniel Ré, Adrienne de Labarthe, Olivier Fitoussi, Chanaz Lounis, Ronan Garlantezec, Olivier Decaux","doi":"10.1016/j.clml.2025.05.015","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.015","url":null,"abstract":"<p><strong>Introduction: </strong>Anti-CD38 monoclonal antibodies (aCD38) are increasingly used in early lines of therapies in multiple myeloma (MM). Retreatment with aCD38-based regimen is a widely used practice in later lines. However, data coming from clinical trials are currently limited. EMMY is a noninterventional, prospective dynamic cohort study conducted in 73 centers in France to assess the real-life management of MM in France and which can explore the efficacy of aCD38-based retreatment.</p><p><strong>Methods: </strong>Patients who initiated a second line of treatment with aCD38-based combinations after a first exposure to aCD38 were identified and described and the outcomes of progression-free survival (PFS) and overall survival (OS) were estimated.</p><p><strong>Results: </strong>In the EMMY cohort, 286 patients received 2 lines of treatment including aCD38. For all aCD38-retreated patients, median PFS was estimated at 5.1 months. Median PFS was 23.6 m in patients sensitive to aCD38 and 4.6 in nonsensitive patients, P = .0003. Median OS was estimated at 17.3 months for all patients,14.8 months in patients nonsensitive to aCD38, and not reached (NR) in sensitive patients, P = .0004. No significant differences in PFS or OS were observed between the refractory and nonrefractory to aCD38 groups.</p><p><strong>Conclusion: </strong>These results of aCD38 retreatment in a large sample of real-life patients (n = 286) in extensively pretreated patients show that retreatment may be a meaningful strategy for aCD38 sensitive patients. These findings need to be investigated further while the use of aCD38 is emerging as a first-line treatment for newly diagnosed patients.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert Panel.","authors":"Meral Beksaç, Esra Sahli, Ahmed Rabea, Guray Saydam, Anil Tombak, Ahmad Alhuraiji, Enas Yahya Mutahar, Mohamed Hosny, Ayman Alhejazi, Mervat Mattar, Mehmet Sinan Dal, Mahmoud Marashi, Melis Palamar","doi":"10.1016/j.clml.2025.05.019","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.019","url":null,"abstract":"<p><p>Multiple myeloma (MM) remains a substantial cause of mortality in the Middle East and North Africa, with incidence rising in the region. MM is challenging to treat because many people relapse and/or become refractory to standard of care. Additional challenges in the Middle East and North Africa region include reduced access to newer therapies, resulting in poorer outcomes than in other regions. Belantamab mafodotin-a first-in-class antibody-drug conjugate targeting B-cell maturation antigen-has shown significant efficacy in the recent DREAMM-7 and DREAMM-8 phase 3 trials for patients with relapsed/refractory MM. However, participants experienced a high incidence of ocular adverse events, due to the off-target effects of monomethyl auristatin F, a microtubule inhibitor responsible for belantamab mafodotin's antimyeloma activity. Belantamab mafodotin is currently under regulatory review in several countries; thus, healthcare providers need specific regional guidance to manage these ocular side effects. A panel of 13 experts in hematology/oncology and ophthalmology from Turkey, Egypt, Saudi Arabia, the United Arab Emirates and Kuwait developed these practical recommendations. The recommendations, formulated through detailed discussions, evidence review and clinical experience, focused on several themes around identification and management of ocular adverse events with a specific emphasis on prevention of severe ocular events.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia.","authors":"Hannah Goulart, Elias Jabbour, Nicholas J Short, Tapan M Kadia, Naveen Pemmaraju, Koichi Takahashi, Farhad Ravandi, Marina Konopleva, Nitin Jain","doi":"10.1016/j.clml.2025.05.013","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.013","url":null,"abstract":"<p><strong>Background: </strong>Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) represents a high-risk subtype of B-ALL. The disease is driven by a range of kinase-activating mutations, resulting in a similar gene expression profile to that of Ph-positive ALL, and one which may be targetable by JAK- or ABL-directed kinase inhibition.</p><p><strong>Patients and methods: </strong>We conducted a phase I/II trial to explore the safety and efficacy of ruxolitinib or dasatinib in combination with Hyper-CVAD chemotherapy for patients ≥ 10 years of age with relapsed and/or refractory Ph-like ALL (clinicaltrials.gov/NCT02115295).</p><p><strong>Results: </strong>A total of 11 patients were enrolled (ruxolitinib cohort, n = 10; dasatinib cohort, n = 1) with a median age of 24 years. The median number of prior lines of treatment was 3. Genetic aberrations included CRLF2 overexpression (n = 8), HMBOX1-JAK2 fusion (n = 1), IGH-EPOR fusion (n = 1), and NUP214-ABL1 (n = 1). We observed no dose-limiting toxicities in the first 2 cohorts of patients receiving ruxolitinib (15 mg BID, n = 5 and 20 mg BID, n = 3), however enrollment of the third cohort (25 mg BID, n = 2) was terminated early due to slow accrual. The most common ≥ grade 3 adverse events were related to infectious complications. We observed overall low efficacy with 1/10 patients receiving ruxolitinib achieving complete remission with incomplete platelet count recovery.</p><p><strong>Conclusion: </strong>Continued efforts should focus on identifying optimal treatment strategies for this high-risk group of patients.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center.","authors":"Ahmed Mohamed, Emily C Zabor, Meera Patel, Hadil Zureigat, Moath Albliwi, Mark Jinan Chen, Joy Nakitandwe, David S Bosler, Heena Kurish, Akriti G Jain, John C Molina, Sophia Balderman, Abhay Singh, Aaron T Gerds, Sudipto Mukherjee, Hetty E Carraway, Anjali S Advani, Moaath K Mustafa Ali","doi":"10.1016/j.clml.2025.05.012","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.012","url":null,"abstract":"<p><strong>Background: </strong>Survival outcomes of acute lymphoblastic leukemia (ALL) in adults remain inferior to those in the pediatric population. Limited data is present directly comparing different first-line intensive regimens in adult patients with ALL.</p><p><strong>Methods: </strong>We conducted a retrospective study comparing outcomes of first-line intensive chemotherapeutic regimens utilized in adult ALL patients at Cleveland Clinic. Outcomes included composite complete response (CCR), minimal residual disease (MRD) flow cytometry (FC-MRD) response, overall survival (OS) and event-free survival (EFS). Multivariable regression and propensity score (PS) weighting were used for adjustment.</p><p><strong>Results: </strong>Out of 161 adult patients with ALL between January, 2017 and August, 2023, 100 received an intensive regimen. Of those, 33% (n = 33) received a pediatric-inspired regimen (PIR) (CALGB-10403, n = 32 (97%)), 39% (n = 39) received CALGB-19802, and 28% (n = 28) received Hyper-CVAD. The median age (IQR) was 27 (21-34) for PIR group, 59 (52-65) years for CALGB-19802 group, and 57 (41-66) years for Hyper-CVAD group. The CCR rates were 88%, 82%, and 81% in PIR, CALGB-19802, and Hyper-CVAD groups. The 3-year OS was 78% (95% CI, 63-95), 58% (95% CI, 44-77), and 70% (95% CI, 52-93) (P = .2) in the above groups, respectively. Hyper-CVAD was associated with a higher odds of FC-MRD negative response to CALGB-19802 (PS-adjusted odds ratio: 3.72, 95% CI, 1.05-14.7, P = .041). The 3-year PS-adjusted OS in Hyper-CVAD was 71% (95% CI, 52-97) compared to 49% (95% CI, 33-73) in CALGB-19802 (P = .14).</p><p><strong>Conclusions: </strong>Compared to an asparaginase-utilizing regimen, CALGB-19802, Hyper-CVAD was associated with higher FC-MRD negative responses. The long-term survival outcomes for patients receiving PIR in young individuals were comparable to those of Hyper-CVAD. Future combination therapies involving blinatumomab and inotuzumab ozogamicin are expected to enhance these outcomes.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | Update on Tailoring Therapy in T Cell Lymphomas.","authors":"Christina Moe, Jasmine Zain","doi":"10.1016/j.clml.2025.05.009","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.009","url":null,"abstract":"<p><p>Peripheral T cell lymphomas are rare and heterogenous diseases with no clear curative options in the relapsed setting. Treatments based on paradigms for aggressive B cell lymphomas have yielded poor outcomes and there is an immense need for therapies that are directed towards PTCL. Understanding the biology and pathologic pathways for this group of diseases has allowed the development of more specific targeted therapies. The are initially evaluated in the relapsed setting with the hope that these agents will then be combined with more traditional lymphoma directed therapies for improved outcomes. This approach has also elucidated that PTCL subtypes differ in biology and treatments should be tailored depending accordingly.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}